Table 3.
Results of various multivariable models testing the observed favorable effect of group TAC/MMF vs. groups TAC/SRL and CSA/SRL combined
| Outcome Variable | Multivariable P-Value of the Group TAC/MMF Effect | Other Significantly Unfavorable Factors (Multivariable P-Value) |
|---|---|---|
| AR Rate1 | P = 0.005 | Non-Caucasian race/ethnicity (P = 0.0004) |
| Younger recipient age (P = 0.0006) | ||
| Donor age ≥50 yr (P = 0.02) | ||
| eGFR at 12 months2 | P = 0.0009 | Donor age (P < 0.0001) |
| eGFR at 24 months2 | P < 0.0001 | Donor age (P < 0.0001) |
| eGFR at 36 months2 | P = 0.008 | Donor age (P < 0.0001) |
| eGFR at 60 months2 | P = 0.02 | Donor age (P < 0.0001) |
| eGFR at 84 months2 | P = 0.02 | Donor age (P = 0.0002) |
1The Cox model for acute reduction (AR) rate provided a multivariable test of the dichotomous variable Group TAC/MMF vs. Groups TAC/SRL and CSA/SRL combined, after controlling for the effects of the other significant factors. In terms of the other significant factors, recipient age (in years) was represented as a continuous variable; the dichotomous variable non-Caucasian race/ethnicity compared Caucasians vs. non-Caucasians (African American, Hispanic, and Other); and the dichotomous variable donor age ≥50 yr compared donor age <50 vs. ≥50 yr.
2The linear regression models for eGFR (at each time point) provided a multivariable test of the dichotomous variable Group TAC/MMF vs. Groups TAC/SRL and CSA/SRL combined, after controlling for the effect of the other significant factor, donor age (continuous variable, in years).